Lantus

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

67 competitors in Type 1 Diabetes Mellitus

#DrugCompanyPhaseTrials

1

Actos

Takeda

Approved

22

Mounjaro

Eli Lilly

Approved

13

Prevacid

Takeda

Approved

—4

Diabeta

Pfizer

Approved

—5

Cellcept

Roche

Approved

—6

Calciferol

Jazz Pharmaceuticals

Approved

—7

Brethine

Sanofi

Approved

—8

Ozempic

Novo Nordisk

Approved

—9

Diamox

Teva

Approved

—10

Cibinqo

Pfizer

Approved

—Show 40 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Type 1 Diabetes Mellitus9 trials

A Study to Compare Pharmacokinetics and Pharmacodynamics of RinGlar® to Lantus® in Type 1 Diabetes Mellitus Patients

Completed·GGeropharm·N/A·NCT04101383·42 enrolled

Non-inferiority Study to Compare the Efficacy and Safety of Mylan's Insulin Glargine With Lantus® in Type 1 Diabetes Mellitus Patients (INSTRIDE 1)

Completed·MMylan Inc.·Phase 3·NCT02227862·558 enrolled

A Study to Compare LY2963016 to Lantus After a Single Dose to Participants With Type 1 Diabetes Mellitus

Completed·Eli Lilly·Phase 1·NCT01600950·20 enrolled

Show 6 more trials

A Study of LY2963016 Compared to Lantus® in Adult Chinese Participants With Type 1 Diabetes Mellitus

Completed·Eli Lilly·Phase 3·NCT03338023·272 enrolled

A Study Comparing the Efficacy and Safety of the Morning Injection of Toujeo Versus Lantus in Patients With Type 1 Diabetes Mellitus

Completed·Sanofi·Phase 4·NCT02688933·638 enrolled

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 1 Diabetes Mellitus

Completed·Sanofi·Phase 3·NCT01683266·549 enrolled

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 1 Diabetes Mellitus on Basal Plus Mealtime Insulin

Completed·Sanofi·Phase 2·NCT01658579·59 enrolled

Extension Study to Assess Safety and Efficacy of Mylan's Insulin Glargine and Lantus® in Type 1 Diabetes Mellitus (T1DM) Patients

Completed·MMylan Inc.·Phase 3·NCT02666430·127 enrolled

A Study of the Safety and Efficacy of MK-1293 Compared to Lantus™ in Participants With Type 1 Diabetes Mellitus (T1DM) (MK-1293-003)

Completed·Merck & Co.·Phase 3·NCT02059161·508 enrolled

Type 2 Diabetes Mellitus6 trials

Dose Range Finding Study of MK-0941 in Patients With Type 2 Diabetes Mellitus on Insulin (MK-0941-007 AM3 EXT1 AM1)(TERMINATED)

Terminated·Merck & Co.·Phase 2·NCT00767000·813 enrolled

Non-inferiority Study to Compare the Efficacy and Safety of Mylan's Insulin Glargine With Lantus® in Type 2 Diabetes Mellitus Patients (INSTRIDE 2)

Completed·MMylan Inc.·Phase 3·NCT02227875·560 enrolled

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin

Completed·Sanofi·Phase 3·NCT01499082·807 enrolled

Show 3 more trials

The Safety and Efficacy of MK-1293 Versus Lantus™ in Participants With Type 2 Diabetes Mellitus (MK-1293-006)

Completed·Merck & Co.·Phase 3·NCT02059187·531 enrolled

A Study of LY2963016 Compared to Lantus® in Adult Chinese Participants With Type 2 Diabetes Mellitus

Completed·Eli Lilly·Phase 3·NCT03338010·536 enrolled

A Study of LY2963016 Compared to LANTUS® in Adult Participants With Type 2 Diabetes Mellitus

Completed·Eli Lilly·Phase 3·NCT02302716·493 enrolled

Type 2 Diabetes5 trials

A Trial to Compare the Pharmacodynamic and Pharmacokinetic Properties of Biochaperone® Combo With Humalog® Mix25 and With Simultaneous Injections of Humalog® and Lantus® in Subjects With Type 2 Diabetes

Completed·AAdocia·Phase 1·NCT02514850·24 enrolled

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy

Completed·Sanofi·Phase 3·NCT01499095·811 enrolled

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy

Completed·Sanofi·Phase 3·NCT01676220·878 enrolled

Show 2 more trials

A Study in Adults With Type 2 Diabetes

Completed·Eli Lilly·Phase 3·NCT01421459·759 enrolled

A Trial to Compare Post Prandial Blood Glucose Control of BioChaperone® Combo With Humalog® Mix25 and With Simultaneous Injections of Humalog® and Lantus® in Subjects With Type 2 Diabetes

Completed·AAdocia·Phase 1·NCT02915250·36 enrolled

ART2 trials

A Study of Insulin Glargine (LY2963016) in Healthy Chinese Participants

Completed·Eli Lilly·Phase 1·NCT03555305·58 enrolled

A Study of LY2963016 in Healthy Participants

Completed·Eli Lilly·Phase 1·NCT01634165·24 enrolled

Treatment2 trials

Glycemic Optimization Treatment Study

Completed·Sanofi·Phase 4·NCT00552370·5,062 enrolled

Determine Whether Glycemic Control is Different Between Lantus & a 3rd Oral Agent When Failure With Other Treatment

Completed·Sanofi·Phase 3·NCT00046462·240 enrolled

10 more indications

GAN2 trials

Gan & Lee Insulin Glargine Target Type (1) Evaluating Research

Completed·GGan and Lee Pharmaceuticals, USA·Phase 3·NCT03371082·576 enrolled

Gan & Lee Insulin Glargine Target Type (2) Evaluating Research

Completed·GGan and Lee Pharmaceuticals, USA·Phase 3·NCT03371108·567 enrolled

Type 1 Diabetes2 trials

Compare Blood Sugar Level Between Lantus in the Morning and Other Insulins in Type 1 Diabetes Adolescents

Completed·Sanofi·Phase 3·NCT00046501·250 enrolled

A Study in Adults With Type 1 Diabetes

Completed·Eli Lilly·Phase 3·NCT01421147·536 enrolled

Single Dose1 trial

A Comparison of LY2963016 to a Basal Insulin After a Single Dose in Healthy Subjects

Completed·Eli Lilly·Phase 1·NCT01374178·16 enrolled

Type 1 Diabetic1 trial

Immunogenicity Safety Study of Wockhardt's Recombinant Insulin Analogue in Type 1 Diabetic Patients

Withdrawn·WWockhardt·Phase 3·NCT01352663

Retinopathy1 trial

Comparison of Diabetes Retinopathy Among Type 2 Diabetic Patients Treated With Different Regimens

Unknown status·TThird Affiliated Hospital, Sun Yat-Sen University·Phase 1·NCT02587741·600 enrolled

PreDiabetes1 trial

Lantus in Prediabetes

Completed·Sanofi·Phase 1·NCT00348972·20 enrolled

Aged1 trial

Comparison of Lantus and Neutral Protamine Hagedorn (NPH) Insulin in the Dawn Phenomenon

Completed·MMassachusetts General Hospital·Phase 3·NCT00694122·27 enrolled

Tics1 trial

A Study to Compare the Pharmacokinetics and Pharmacodynamics of LY2963016 to Lantus in Healthy Participants

Completed·Eli Lilly·Phase 1·NCT01476345·80 enrolled

Sudden Sensorineural Hearing Loss (SSNHL)1 trial

Steroid-induced Hyperglycemia Management With Insulin Patch Pump in Sudden Sensorineural Hearing Loss: a CGM-guided Exploratory Randomized Controlled Trial (SHIP Trial)

Not yet recruiting·HHallym University·Preclinical·NCT07652528·50 enrolled

Unspecified3 trials

Perioperative Insulin Glargine Dosing Study

Completed·TTamra Dukatz·Phase 4·NCT00309465·402 enrolled

Phenotype Evaluation in Insulin Naive Patients Using Lantus (Insulin Glargine)

Completed·Sanofi·Phase 4·NCT00653302·280 enrolled

LANN-study: Lantus, Amaryl, Novorapid, Novomix Study

Completed·RRijnstate Hospital·Phase 3·NCT00151697·150 enrolled

Details

Drug Info

Related News